Home » Regeneron Begins Phase 3 Trial of Antibody Cocktail for COVID-19
Regeneron Begins Phase 3 Trial of Antibody Cocktail for COVID-19
Regeneron Pharmaceuticals has begun a phase 3 clinical trial in the U.S. of its antibody cocktail REGN-COV2 for the prevention of COVID-19 infections.
The trial is being conducted with the National Institutes for Allergy and Infectious Diseases and plans to enroll 2,000 patients across 100 sites.
The company has also launched two phase 2/3 trials evaluating the cocktail’s ability to treat patients already infected with COVID-19.
Upcoming Events
-
21Mar
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr